Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel-MedSci.cn

Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel

Van Cutsem, E; Collignon, J; Eefsen, R; Ochsenreither, S; Zvirbule, Z; Ivanauskas, A; Millrud, CR; Skoog, P; Losic, N; Magnusson, S; Sanfridson, A; Liberg, D

CANCER RESEARCH, 2023; 83 (7):

科室
- - 订阅+
  - 更多科室
工具
服务